Gail J. Roboz

Gail J. Roboz, MD is Professor of Medicine and Director of the Leukemia Program at Weill Cornell Medicine and Attending Physician at NewYork-Presbyterian Hospital in New York City. She is one of the most prolific and innovative AML clinical trialists in the United States, widely recognized for her commitment to advancing treatment for difficult-to-treat AML populations and for her work on novel therapeutics across multiple disease subtypes. Dr. Roboz is a principal investigator in the landmark QUANTUM-First trial — the phase III study of quizartinib (a selective FLT3-ITD inhibitor) added to standard induction and consolidation chemotherapy in newly diagnosed FLT3-ITD-positive AML — which demonstrated significantly improved overall survival (HR 0.78; p=0.032) versus placebo, leading to FDA approval of quizartinib in July 2023. She has been a key investigator in multiple pivotal trials of CPX-351 (liposomal daunorubicin+cytarabine) in secondary AML, sapacitabine in elderly AML, and has led numerous early-phase trials at Weill Cornell exploring novel compounds. Dr. Roboz is also recognized for her pioneering work on AML response criteria and MRD assessment, co-chairing the ELN MRD Working Party and leading efforts to standardize MRD endpoints in AML trials. She is known for her energetic mentorship, patient advocacy, and as a frequent public communicator about AML, and has authored over 250 publications.